Search Results

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (“Taro” or the “Company”) today announced that it has called an extraordinary general meeting of its shareholders (the “Extraordinary General Meeting”), to be held on May 22, 2024, at 10:00 a.m., Israel time.

Sun Pharmaceutical Industries Limited today announced the successful completion of the merger of Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (“Taro”) with its subsidiary.

Sun Pharmaceutical Industries Limited and Taro Pharmaceutical Industries Ltd. announced that the merger agreement between Taro and Sun Pharma was approved by the affirmative vote of Taro shareholders at an Extraordinary General Meeting and an Ordinary Class Meeting on May 22, 2024.

Taro Pharmaceutical Industries Ltd. provided unaudited financial results for the quarter and year ended March 31, 2024.

Taro Pharmaceutical Industries Ltd. announced that it plans to release its financial results for year ended March 31, 2024, after the close of market on Monday, May 20, 2024.

Taro Pharmaceutical Industries Ltd. provided unaudited financial results for the quarter and nine months ended December 31, 2023.

Sun Pharmaceutical Industries Limited and Taro Pharmaceutical Industries Ltd. announced that they have entered into a definitive merger agreement in which Sun Pharma, Taro’s controlling shareholder, has agreed to acquire all of the outstanding ordinary shares of Taro other than the shares already held by Sun Pharma or its affiliates for US$43.00 per share in cash without interest.

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (“Taro” or the “Company”) today provided unaudited financial results for the quarter and six months ended September 30, 2023.

Taro Pharmaceutical Industries Ltd. announced that it plans to release its financial results for the third quarter ended December 31, 2023, after the close of market on Thursday, January 25, 2024.